We conducted a phase 3 randomized controlled trial looking at the immunogenicity and safety of a novel combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine, Hib-MenC-TT in a 2-, 3-, and 4-month primary infant immunization schedule. SBA MenC titers > or =1:8 and anti-PRP concentrations > or =0.15 microg/mL were measured in 99.2% and 100%, respectively, of the infants receiving Hib-MenC-TT.
Journal article
2007-11-01T00:00:00+00:00
26
1057 - 1059
2
Antibodies, Bacterial, Diphtheria-Tetanus-Pertussis Vaccine, Haemophilus Infections, Haemophilus Vaccines, Haemophilus influenzae type b, Humans, Immunization, Immunization Schedule, Infant, Meningococcal Infections, Meningococcal Vaccines, Neisseria meningitidis, Serogroup C, Poliovirus Vaccine, Inactivated, Tetanus Toxoid, Vaccines, Combined, Vaccines, Conjugate